FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020046121> ?p ?o ?g. }

• W2020046121 endingPage "146" @default.
• W2020046121 startingPage "136" @default.
• W2020046121 abstract "This multi-centre, randomized, double-blind, double-dummy, parallel-group study was designed to investigate the hypothesis of equivalent efficacy and comparable safety of two inhaled presentations of salmeterol/fluticasone propionate combination product (SALM/FP) 50/100 microg administered twice daily to patients with mild-to-moderate asthma for 12 weeks. The delivery systems were a 25/50 microg strength hydrofluoroalkane (HFA) metered-dose inhaler (MDI) and a Diskus inhaler (50/100 microg strength). A third group received FP 100 microg twice daily via a chlorofluorocarbon MDI (50 microg strength). A total of 497 patients aged 11-79 years with reversible airways obstruction who were symptomatic on inhaled corticosteroid (ICS) therapy and had room for improvement in lung function were randomized to treatment in a double-blind, parallel-group design (SALM/FP MDI: n=165; SALM/FP Diskus: n=167; FP MDI: n=165) for 12 weeks. A total of 383 patients completed the study according to the protocol. According to the primary efficacy variable, increase in mean morning PEF over weeks 1-12, the two inhaled presentations of SALM/FP were clinically equivalent (adjusted mean increases 43 and 46 l min(-1); treatment difference 3 l min(-1); 95% confidence interval: -6 to 11 l min(-1)). Equivalence was also demonstrated by all secondary efficacy measures. The SALM/FP MDI was significantly superior to the FP MDI for increase in mean morning PEF (treatment difference 19 l min(-1); P<0.001) and for all secondary measures except FEV1 and symptom-free nights. There was no significant difference between the groups with respect to adverse events and serum cortisol levels. These results demonstrate that the SALM/FP 25/50 microg HFA MDI (two inhalations twice daily) is clinically equivalent to the SALM/FP 50/100 microg Diskus (one inhalation twice daily). Patients switching to SALM/FP from other MDI-based asthma treatments may now do so without a change of delivery device." @default.
• W2020046121 created "2016-06-24" @default.
• W2020046121 creator A5021692088 @default.
• W2020046121 creator A5056670402 @default.
• W2020046121 creator A5090062530 @default.
• W2020046121 date "2001-02-01" @default.
• W2020046121 modified "2023-10-17" @default.
• W2020046121 title "Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma" @default.
• W2020046121 cites W1723887941 @default.
• W2020046121 cites W1902445705 @default.
• W2020046121 cites W1975409885 @default.
• W2020046121 cites W1987062528 @default.
• W2020046121 cites W1990951259 @default.
• W2020046121 cites W2013037468 @default.
• W2020046121 cites W2019849031 @default.
• W2020046121 cites W2021365261 @default.
• W2020046121 cites W2022008229 @default.
• W2020046121 cites W2027285152 @default.
• W2020046121 cites W2066887358 @default.
• W2020046121 cites W2083269086 @default.
• W2020046121 cites W2092027437 @default.
• W2020046121 cites W2098633046 @default.
• W2020046121 cites W2099545157 @default.
• W2020046121 cites W2121545123 @default.
• W2020046121 cites W2132520035 @default.
• W2020046121 cites W2151442988 @default.
• W2020046121 cites W2167495641 @default.
• W2020046121 cites W2331287401 @default.
• W2020046121 cites W4252302175 @default.
• W2020046121 doi "https://doi.org/10.1053/rmed.2000.1008" @default.
• W2020046121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11217910" @default.
• W2020046121 hasPublicationYear "2001" @default.
• W2020046121 type Work @default.
• W2020046121 sameAs 2020046121 @default.
• W2020046121 citedByCount "51" @default.
• W2020046121 countsByYear W20200461212012 @default.
• W2020046121 countsByYear W20200461212013 @default.
• W2020046121 countsByYear W20200461212014 @default.
• W2020046121 countsByYear W20200461212016 @default.
• W2020046121 countsByYear W20200461212018 @default.
• W2020046121 countsByYear W20200461212020 @default.
• W2020046121 countsByYear W20200461212022 @default.
• W2020046121 crossrefType "journal-article" @default.
• W2020046121 hasAuthorship W2020046121A5021692088 @default.
• W2020046121 hasAuthorship W2020046121A5056670402 @default.
• W2020046121 hasAuthorship W2020046121A5090062530 @default.
• W2020046121 hasBestOaLocation W20200461211 @default.
• W2020046121 hasConcept C121332964 @default.
• W2020046121 hasConcept C126322002 @default.
• W2020046121 hasConcept C153294291 @default.
• W2020046121 hasConcept C168563851 @default.
• W2020046121 hasConcept C19720800 @default.
• W2020046121 hasConcept C2776042228 @default.
• W2020046121 hasConcept C2776719499 @default.
• W2020046121 hasConcept C2776804153 @default.
• W2020046121 hasConcept C2776954882 @default.
• W2020046121 hasConcept C2777419714 @default.
• W2020046121 hasConcept C2779017260 @default.
• W2020046121 hasConcept C2779028295 @default.
• W2020046121 hasConcept C2780261241 @default.
• W2020046121 hasConcept C2780667556 @default.
• W2020046121 hasConcept C2781018748 @default.
• W2020046121 hasConcept C2781212218 @default.
• W2020046121 hasConcept C42219234 @default.
• W2020046121 hasConcept C44249647 @default.
• W2020046121 hasConcept C71924100 @default.
• W2020046121 hasConceptScore W2020046121C121332964 @default.
• W2020046121 hasConceptScore W2020046121C126322002 @default.
• W2020046121 hasConceptScore W2020046121C153294291 @default.
• W2020046121 hasConceptScore W2020046121C168563851 @default.
• W2020046121 hasConceptScore W2020046121C19720800 @default.
• W2020046121 hasConceptScore W2020046121C2776042228 @default.
• W2020046121 hasConceptScore W2020046121C2776719499 @default.
• W2020046121 hasConceptScore W2020046121C2776804153 @default.
• W2020046121 hasConceptScore W2020046121C2776954882 @default.
• W2020046121 hasConceptScore W2020046121C2777419714 @default.
• W2020046121 hasConceptScore W2020046121C2779017260 @default.
• W2020046121 hasConceptScore W2020046121C2779028295 @default.
• W2020046121 hasConceptScore W2020046121C2780261241 @default.
• W2020046121 hasConceptScore W2020046121C2780667556 @default.
• W2020046121 hasConceptScore W2020046121C2781018748 @default.
• W2020046121 hasConceptScore W2020046121C2781212218 @default.
• W2020046121 hasConceptScore W2020046121C42219234 @default.
• W2020046121 hasConceptScore W2020046121C44249647 @default.
• W2020046121 hasConceptScore W2020046121C71924100 @default.
• W2020046121 hasIssue "2" @default.
• W2020046121 hasLocation W20200461211 @default.
• W2020046121 hasLocation W20200461212 @default.
• W2020046121 hasOpenAccess W2020046121 @default.
• W2020046121 hasPrimaryLocation W20200461211 @default.
• W2020046121 hasRelatedWork W1998329899 @default.
• W2020046121 hasRelatedWork W1999139619 @default.
• W2020046121 hasRelatedWork W2020046121 @default.
• W2020046121 hasRelatedWork W2040897701 @default.
• W2020046121 hasRelatedWork W2061424141 @default.
• W2020046121 hasRelatedWork W2095324820 @default.
• W2020046121 hasRelatedWork W2158529533 @default.
• W2020046121 hasRelatedWork W2984327395 @default.

• next